SEC Tracker
Get the app
OLMA · XBRL financial data

Olema Pharmaceuticals financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (OLMA's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Research and development19,45325,872*29,88329,10933,22632,299*30,62443,90239,95143,220*49,23257,785
General and administrative3,8894,544*4,4564,4214,3954,469*4,2493,9625,9266,864*8,7549,394
Total operating expenses23,34230,416*34,33933,53037,62136,768*34,87347,86445,87750,084*57,98667,179
Operating income (loss)(23,342)(30,416)*(34,339)(33,530)(37,621)(36,768)*(34,873)(47,864)(45,877)(50,084)*(57,986)(67,179)
Interest income1,9193,551*3,3523,1082,9283,294*4,5244,0423,6484,010*4,7764,507
Other income (expense)(79)93*1740138(93)*(40)381213*121(528)
Income tax expense (benefit)—year only———year only———year only——
Net income (loss)(21,502)(26,772)*(30,970)(30,382)(34,555)(33,567)*(30,389)(43,784)(42,217)(46,061)*(53,089)(63,200)
Earnings per share, basic USD per share(0.48)(0.49)*(0.56)(0.54)(0.60)(0.51)*(0.36)(0.51)(0.49)(0.50)*(0.52)(0.61)
Earnings per share, diluted USD per share(0.48)(0.49)*(0.56)(0.54)(0.60)(0.51)*(0.36)(0.51)(0.49)(0.50)*(0.52)(0.61)
Weighted average shares, basic thousands of shares44,97754,781*55,57456,28257,26365,793*85,42685,49785,73291,317*102,800104,454
Weighted average shares, diluted thousands of shares44,97754,781*55,57456,28257,26365,793*85,42685,49785,73291,317*102,800104,454

Balance sheet

CSV

Fiscal quarters (OLMA's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Cash and cash equivalents117,40768,53933,72016,89235,888139,48050,64052,47335,26048,30152,54748,599
Marketable securities159,494193,268215,257222,212178,875294,606342,067309,440293,700457,136452,800412,471
Prepaid and other current assets5,1074,7063,1133,0833,2314,3873,9565,8125,36910,0157,8828,806
Total current assets282,008266,513252,090242,187217,994438,473396,663367,725334,329515,452513,229469,876
Property and equipment, net1,0569681,033945849746653560486274356382
Right-of-use asset2,5582,2912,0551,8141,5671,3141,0551,6851,4191,146921638
Total assets292,799276,945263,694254,557230,173450,979409,639382,002352,453533,430530,645486,578
Accounts payable2,2072,6987,6564,3542,6854,4601519343,4749,2533,7191,667
Total current liabilities15,96621,62126,22426,53530,70041,75826,06433,16441,65551,80247,16753,014
Lease liability, non-current1,6991,4291,1528595622571236023106900
Total liabilities17,66523,05027,37627,39431,26242,01526,18736,76644,96554,87150,16756,014
Accumulated deficit(278,860)(305,632)(336,602)(366,984)(401,539)(435,106)(465,495)(509,279)(551,496)(597,557)(650,646)(713,846)
Total stockholders' equity275,134253,895236,318227,163198,911408,964383,452345,236307,488478,559480,478430,564
Total liabilities and equity292,799276,945263,694254,557230,173450,979409,639382,002352,453533,430530,645486,578
Common shares outstanding (cover page) thousands of shares54,77055,91555,93457,26657,29868,33368,42168,63468,66087,15787,34787,498

Cash flows

CSV

Fiscal quarters (OLMA's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Net income (loss)(21,502)(26,772)*(30,970)(30,382)(34,555)(33,567)*(30,389)(43,784)(42,217)(46,061)*(53,089)(63,200)
Stock-based compensation4,105*4,351*4,9095,724*5,626*6,323*4,3784,692*4,250*4,266*10,14812,903*
Depreciation and amortization90*88*8894*95*116*128132*43*187*119102*
Net cash from operating activities(22,744)*(18,476)*(23,496)(27,555)*(27,016)*(26,284)*(43,979)(29,883)*(34,527)*(38,327)*(45,987)(45,896)*
Purchases of property and equipment——1536*0*0*——0*———
Net cash from investing activities(25,436)*(30,915)*(20,144)(4,878)*45,920*(114,424)*(45,083)34,234*17,273*(162,184)*4,52940,841*
Net cash from financing activities130,629*523*8,82115,605*92*244,300*222(2,518)*41*213,552*45,7041,107*
Net change in cash82,449*(48,868)*(34,819)(16,828)*18,996*103,592*(88,840)1,833*(17,213)*13,041*4,246(3,948)*

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($K)Revenue, quarter ($K)Operating cash flow, quarter ($K)Shares outstandingRunwayQuarter
Olema Pharmaceuticals48,599not reported(45,896)*87.5M10.0 quarters 10-QJun 30, 2026
Annexon199,270not reported(48,007)*not reported4.4 quarters 10-QJun 30, 2026
DBV Technologies165,7001,600(51,500)*314.4M3.2 quarters 10-QSep 30, 2026
Heron Therapeutics20,721not reported(2,213)*189.9M19.3 quarters 10-QJun 30, 2026
Corvus Pharmaceuticals15,013not reported(12,215)*84.4M15.7 quarters 10-QSep 30, 2026
Verastem172,80124,012(33,593)*126.0M4.0 quarters 10-QSep 30, 2026
Aldeyra Therapeutics40,975not reported(4,124)*60.4M— 10-QSep 30, 2026
Sagimet Biosciences165,896not reported(11,099)*not reported23.2 quarters 10-QJun 30, 2026
Atea Pharmaceuticals76,548not reported(37,084)*80.2M5.9 quarters 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.

Data on this page was fetched . The filing on SEC.gov is the record.